Abscisic Acid Dosing for Glycemic Control Without Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes mellitus, such as insulinagogue drugs and PPAR-γ stimulators, lead to excessive insulin secretion and beta-cell depletion, while existing 'energizing' preparations fail to effectively stimulate peripheral glucose consumption, often causing side effects due to stimulants like caffeine.
Innovation Solution
The use of abscisic acid (ABA) or its hydrolysable conjugates, like ABA-glucosyl ester, at a low oral dose (0.15-95 μg/day/kg) to improve glycemic control without increasing insulin secretion, achieved through oral administration or dietary intake of ABA-rich foods like apricots and figs, using solvent-free extraction methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulinagogue drugs or PPAR-γ stimulators are used to treat type 2 diabetes, then glycemic control is improved, but excessive insulin secretion occurs leading to beta-cell depletion
Solution Approach 1:
The patent changes the therapeutic approach from insulin secretion stimulation to direct glucose metabolism modulation by using abscisic acid at specific low doses (0.15-95 μg/day/kg), which alters the mechanism of action to improve glycemic control without overstimulating insulin secretion
Solution Approach 2:
Abscisic acid acts as an intermediary substance that mediates glucose metabolism through alternative pathways, bypassing the harmful insulin secretion mechanism while still achieving glycemic control through its effect on glucose uptake and utilization
2Use of energy by moving object
If conventional 'energizing' preparations containing stimulants like caffeine are used to stimulate peripheral glucose consumption, then energy metabolism is activated, but side effects occur on the central nervous system and cardiovascular system
Solution Approach 1:
The patent extracts and isolates the beneficial metabolic effect of glucose consumption stimulation while removing the harmful stimulant components (caffeine and other cardiovascular stimulants) from conventional energizing preparations, achieving selective activation of peripheral glucose uptake without systemic side effects
Solution Approach 2:
The patent replicates the desired physiological effect of enhanced peripheral glucose consumption achieved by natural exercise or metabolic activation, but through a safe pharmacological mechanism using abscisic acid that copies the beneficial metabolic outcome without the harmful stimulant pathway
3Reliability
If high doses of abscisic acid are administered to improve glucose tolerance, then glycemic control improves, but the required dose is too high for practical oral administration
Solution Approach 1:
The patent identifies and exploits a specific dose-response relationship where low doses (0.15-95 μg/day/kg) of abscisic acid produce the desired glucose tolerance improvement, representing a parameter change from previously required high doses to practically administrable low doses
Solution Approach 2:
The patent demonstrates that a small fraction (partial action) of the previously required dose is sufficient to achieve the therapeutic effect, showing that 0.15-95 μg/day/kg provides adequate glucose tolerance improvement without the need for excessive administration
Data Source
AI summary
The invention relates to the use of a very low dosage form of abscisic acid (ABA) or an in vivo hydrolysable conjugate thereof, preferably ABA-glucosyl ester (ABA-GE), for nutracentic/therapeutic use for controlling and/or preventing hyperglycaemia and weight gain in response to sugar intake with a reduction in insulin secret and an increase in muscle performance.